文献速递肿瘤 PET/CT核素与放射性配体治疗

双示踪剂PET病灶水平生物标志物预测多发性骨髓瘤CXCR4靶向核素治疗预后

Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-18

结果显示,髓内一致性病灶的FDG摄取与治疗反应和生存相关,CXCR4阳性髓内肿瘤负荷及表面标准化最大病灶间距离提供额外生存信息。

要点

  • 髓内一致性病灶FDG-SUVmean较低者治疗反应更好(Welch p=0.03)。
  • TLG[FDG髓内一致性]、sDmax[FDG]及CXCR4阳性髓内负荷较高与总生存期较短相关(log-rank p<0.05)。
  • 双示踪剂PET/CT一致性感知的病灶水平定量有助于CXCR4-RPT风险分层。

核心结论

  • 髓内一致性病灶的[18F]FDG摄取与治疗反应和生存均相关,CXCR4表达髓内体积和sDmax补充生存信息。
  • 双示踪剂PET/CT一致性感知的病灶水平定量可能有助于CXCR4靶向RPT的风险分层,但需前瞻性大样本验证。

研究设计与样本

  • 采用全自动流程进行深度学习病灶分割和双示踪剂融合,经批质量控制与校正确保分割准确性,并以>10%体积重叠判定一致性病灶。
  • 提取人口学、实验室/遗传学变量及FDG和CXCR4 PET影像指标,按解剖部位(髓内 vs 髓外)和一致性(一致 vs 不一致)分层,并计算表面标准化最大病灶间距离(sDmax)。
  • 终点为治疗反应(基于IMWG标准血清学或PET/MRI评估的缓解者 vs 非缓解者)和总生存期(OS)。
  • 组间比较采用Welch t检验/卡方检验,生存分析采用Kaplan-Meier估计和log-rank检验,决策树模型用SHAP解释。

主要发现

  • 缓解者髓内和髓外一致性病灶的[18F]FDG-SUVmean较低(Welch p=0.03)。
  • 反应分类器中,上述指标与部分髓外CXCR4优势不一致特征及高危细胞遗传学并列SHAP排名前列预测因子。
  • 较短OS与较高TLG[FDG髓内一致性]、较大sDmax[FDG]及较高CXCR4阳性髓内负荷(MTV/TLC)相关(log-rank p<0.05)。
  • SHAP方向性与单变量趋势一致;BMI在6个月生存模型中与早期死亡呈适度负相关。

关键数值与推荐

  • 一致性病灶定义为FDG和CXCR4阳性病灶体积重叠>10%。
  • 治疗反应依据IMWG标准血清学评估或PET/MRI评估分为缓解者与非缓解者。
  • 统计学显著性阈值未在摘要中明示,仅报告Welch p=0.03和log-rank p<0.05。

临床怎么用

  • 对拟行CXCR4靶向RPT的复发难治多发性骨髓瘤患者,可考虑双示踪剂PET/CT评估病灶一致性和定量参数以辅助风险分层。
  • 髓内一致性病灶FDG摄取、CXCR4阳性髓内负荷及sDmax等指标可能帮助识别治疗反应和生存预后不同的患者。

局限性

  • 探索性、假设生成性分析,样本量小(22例),需前瞻性大样本验证。
  • 回顾性设计,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: C-X-C motif chemokine receptor 4 (CXCR4)-directed radiopharmaceutical therapy (RPT) represents a promising option for hematologic malignancies. Nevertheless, responses in relapsed and refractory (r/r) multiple myeloma (MM) are heterogenous, emphasizing the need for optimized patient selection before RPT. Current approaches mostly rely on qualitative assessments, confirming relevant CXCR4-expression by CXCR4-directed PET in vital myeloma burden, the latter usually being determined by additional [18F]FDG-PET. PURPOSE: To evaluate whether quantitative imaging biomarkers derived from dual-tracer PET/CT can enhance patient stratification and predict therapeutic response and survival following CXCR4-RPT. MATERIALS AND METHODS: 22 patients with r/r MM who underwent CXCR4-directed [⁶⁸Ga]Ga-PentixaFor-PET/CT and [¹⁸F]FDG-PET/CT imaging prior to CXCR4-RPT were retrospectively analyzed. A fully automated pipeline performed deep-learning-based lesion segmentation and dual-tracer fusion; batch quality control and correction ensured segmentation accuracy and concordant-lesion adjudication (> 10% volumetric overlap) prior to lesion-level feature extraction. Features included demographics, laboratory/genetic variables, and imaging metrics from FDG- and CXCR4-PET, stratified by anatomic site (medullary vs. extramedullary) and concordance (concordant vs. discordant as defined by comparing FDG- and CXCR4-positive myeloma lesions). Surface-standardized maximum inter-lesion distances (sDmax) were additionally computed. Endpoints were therapy response (responder vs. non-responder as defined by serological response assessment based on IMWG-criteria or PET/MRI based response assessment) and overall survival (OS). Group comparisons were performed using Welch's t-test/Chi-square; survival analysis was conducted applying Kaplan-Meier estimates and log-rank tests. Decision-tree models were interpreted with SHapley Additive exPlanations (SHAP). RESULTS: Responders to RPT showed lower [18F]FDG-SUVmean in medullary and extramedullary concordant lesions (Welch's p = 0.03). In the response classifier, these metrics ranked among the top predictors by SHAP, alongside selected extramedullary CXCR4-dominant discordant features and high-risk cytogenetics. Shorter OS was associated with higher TLG[FDG medullary concordant], greater sDmax[FDG], and higher CXCR4-positive medullary burden (MTV/TLC) (log-rank p < 0.05). SHAP directionality agreed with univariate trends. BMI showed a modest inverse association with early mortality in the 6-month survival model. CONCLUSIONS: In our exploratory analysis, [¹⁸F]FDG-uptake within medullary concordant lesions was linked to both response and survival, while CXCR4-expressing medullary volume and sDmax added survival information. Concordance-aware, lesion-level quantification from dual-tracer PET/CT might present as a promising approach to aid risk stratification for CXCR4-directed RPT. However, initial findings of our hypothesis generating analysis warrant prospective validation in larger cohorts.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xue S, Kraus S, Enke JS, et al. Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41706122. doi:10.1007/s00259-026-07814-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。